- Home
- ICCM vs NRSN Comparison
ICCM vs NRSN Comparison
Compare ICCM & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCM
- NRSN
- Stock Information
- Founded
- ICCM 2006
- NRSN 2017
- Country
- ICCM Israel
- NRSN Israel
- Employees
- ICCM N/A
- NRSN N/A
- Industry
- ICCM
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- ICCM
- NRSN Health Care
- Exchange
- ICCM Nasdaq
- NRSN Nasdaq
- Market Cap
- ICCM 61.1M
- NRSN 50.1M
- IPO Year
- ICCM N/A
- NRSN 2021
- Fundamental
- Price
- ICCM $0.83
- NRSN $1.26
- Analyst Decision
- ICCM Strong Buy
- NRSN Buy
- Analyst Count
- ICCM 1
- NRSN 2
- Target Price
- ICCM $2.50
- NRSN $14.00
- AVG Volume (30 Days)
- ICCM 2.6M
- NRSN 368.3K
- Earning Date
- ICCM 08-13-2025
- NRSN 09-29-2025
- Dividend Yield
- ICCM N/A
- NRSN N/A
- EPS Growth
- ICCM N/A
- NRSN N/A
- EPS
- ICCM N/A
- NRSN N/A
- Revenue
- ICCM $3,273,000.00
- NRSN N/A
- Revenue This Year
- ICCM $75.27
- NRSN N/A
- Revenue Next Year
- ICCM $129.39
- NRSN N/A
- P/E Ratio
- ICCM N/A
- NRSN N/A
- Revenue Growth
- ICCM 0.34
- NRSN N/A
- 52 Week Low
- ICCM $0.48
- NRSN $0.60
- 52 Week High
- ICCM $1.66
- NRSN $2.60
- Technical
- Relative Strength Index (RSI)
- ICCM 29.89
- NRSN 33.19
- Support Level
- ICCM $0.87
- NRSN $1.00
- Resistance Level
- ICCM $1.07
- NRSN $1.52
- Average True Range (ATR)
- ICCM 0.07
- NRSN 0.21
- MACD
- ICCM -0.02
- NRSN -0.07
- Stochastic Oscillator
- ICCM 0.26
- NRSN 23.64
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.